- 4 次围观
产品图片
![BEI Resources生物材料图片 BEI Resources生物材料图片](/sites/default/files/Data96/Beiresource_product_image_sample.jpg)
货号/SKU
NR-51602
货号/规格
EA
库存与交货期
3-8周
人民币价格
14000
试剂海关审批
A/B级风险物质只能直接使用人购买并持有实验室有效资质,其它询客服确认
国外采购
支持/部分限制一年内购买数量
厂牌
BEI Resources(ATCC)
产品基础信息
生物安全等级建议分类:美国、2
产品描述信息
NR-51602??Pseudomonas aeruginosa, MRSN 29192(Bacteria)|Pseudomonas aeruginosa|MRSN 29192| -60°C or colder|MRSN/WRAIRAcknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Pseudomonas aeruginosa, Strain MRSN 29192, NR-51602. This strain is part of the Pseudomonas aeruginosa Diversity Panel provided by the Multidrug-Resistant Organism Repository and Surveillance Network (MRSN) at the Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD, USA.”|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
Pseudomonas aeruginosa (P. aeruginosa), strain MRSN 29192 was isolated in 2015 from human urine as part of a surveillance program in the United States.
P. aeruginosa, strain MRSN 29192 was deposited as part of the MRSN Pseudomonas aeruginosa Diversity Panel available from BEI Resources as NR-51829. NR-51602 was deposited as multi-locus sequence type (MLST) ST 3010, sensitive to amikacin, gentamicin and tobramycin and resistant to aztreonam, ceftazidime, ciprofloxacin, cefepime, levofloxacin, meropenem and piperacillin/tazobactam with intermediate resistance to imipenem. Strain MRSN 29192 is reported to have a chromosomal aminoglycoside phosphotransferase gene [aph(3')-IIb; conferring resistance to kanamycin A and B, neomycin B and C, butirosin and seldomycin F5], two beta-lactamase genes (blaOXA-50 and blaPAO; conferring resistance to beta-lactams), a chloramphenicol acetyltransferase gene (cat B7; conferring resistance to chloramphenicol) and a fosfomycin-inactivating gene (fosA; conferring resistance to fosfomycin). The complete genome of P. aeruginosa, strain MRSN 29192 is available (GenBank: RXUK00000000).
Note: Environmental and clinical isolates of P. aeruginosa frequently contain viruses known as prophages. During growth, some strains from the Pseudomonas aeruginosa Diversity Panel displayed plaques resulting from the activation of their inherent prophages. Please refer to the Certificate of Analysis to determine if phage plaques were observed for this strain.
Each vial contains approximately 0.5 mL of bacterial culture in Tryptic Soy broth supplemented with 10% glycerol.
Additional information and tools are available at PATRIC (Pathosystems Resource Integration Center).
Pseudomonas aeruginosa (P. aeruginosa), strain MRSN 29192 was isolated in 2015 from human urine as part of a surveillance program in the United States.
P. aeruginosa, strain MRSN 29192 was deposited as part of the MRSN Pseudomonas aeruginosa Diversity Panel available from BEI Resources as NR-51829. NR-51602 was deposited as multi-locus sequence type (MLST) ST 3010, sensitive to amikacin, gentamicin and tobramycin and resistant to aztreonam, ceftazidime, ciprofloxacin, cefepime, levofloxacin, meropenem and piperacillin/tazobactam with intermediate resistance to imipenem. Strain MRSN 29192 is reported to have a chromosomal aminoglycoside phosphotransferase gene [aph(3')-IIb; conferring resistance to kanamycin A and B, neomycin B and C, butirosin and seldomycin F5], two beta-lactamase genes (blaOXA-50 and blaPAO; conferring resistance to beta-lactams), a chloramphenicol acetyltransferase gene (cat B7; conferring resistance to chloramphenicol) and a fosfomycin-inactivating gene (fosA; conferring resistance to fosfomycin). The complete genome of P. aeruginosa, strain MRSN 29192 is available (GenBank: RXUK00000000).
Note: Environmental and clinical isolates of P. aeruginosa frequently contain viruses known as prophages. During growth, some strains from the Pseudomonas aeruginosa Diversity Panel displayed plaques resulting from the activation of their inherent prophages. Please refer to the Certificate of Analysis to determine if phage plaques were observed for this strain.
Each vial contains approximately 0.5 mL of bacterial culture in Tryptic Soy broth supplemented with 10% glycerol.
Additional information and tools are available at PATRIC (Pathosystems Resource Integration Center).
主要内容
此项目的每个订单数量限制为1.此商品每年可订购两次.此限制的订单将在发货前发送到NIAID批准.
假单胞菌铜绿假单胞菌(P. Aerginosa),菌株MRSN 29192于2015年从人类尿中分离为美国监督计划的一部分.
p.铜绿假单胞菌,菌株MRSN 29192被从BEI资源作为.将NR-51602沉积为多基因座序列类型(MLST)ST 3010,对Amikacin,庆大霉素和筛选敏敏敏感,并抵抗阿兹特兰菊,头孢他啶,CiProfloxacin,Cefepime,Levofloxacin,Meropenem和Piperacillin / Tazobactam,具有中间抗性的亚杉抗性.据报道,菌株MRSN 29192具有染色体氨基糖苷磷酸转移酶基因[ APH (3') - IIB;赋予卡那霉素A和B,NeoMycin B和C,丁素和Seldomycin F5]的抵抗力,两个β-内酰胺酶基因( BLA Oxa-50 和 Bla pao ;赋予β-内酰胺酸酯,氯霉素乙酰转移酶基因( cat b7;赋予氯霉素的抗性)和福斯霉素灭活基因( fos a;赋予抗氟哌霉素). p的完整基因组. Aerginosa ,菌株MRSN 29192可用(Genbank: rxuk00000000 ).
注意: p的环境和临床分离株.铜绿假单胞菌经常含有称为前言的病毒.在生长期间,来自假单胞菌铜绿假单胞菌的一些菌株多样性面板显示斑块,由其固有的预言激活产生.请参阅分析证书以确定是否观察到这种菌株的噬菌体斑块.
每个小瓶含有约0.5ml的胰蛋白酶肉汤中的细菌培养,补充有10%甘油.
patric (Pathosystems资源集成中心)提供了其他信息和工具.
厂牌介绍
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立,旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中,可以监控科学界对这些材料的访问和使用,并确保试剂的质量控制。
除了为传染病界提供材料外,BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势,包括安全存储、社区访问和分发;同时保护存款人的知识产权。只要有需要,BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月, ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料,包括由其他政府支持的研究项目存放的材料,将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中,涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。
品牌标识
![BEI Resources BEI Resources 由美国国家过敏和传染病研究所资助,由 ATCC 管理](/sites/default/files/brand_logo/beiresources_logo.jpg)
可能感兴趣的内容
2024-05-19
2022-04-01
2023-10-24
2022-03-31
2024-01-21
2022-04-01
2021-12-21
2021-10-31
2022-04-01
2022-01-10
2022-04-01
2021-12-21
2021-12-13
2024-06-18
2024-05-19